DIAGNOS AI based clinical Eye Test for Diabetic Retinopathy Demonstrates Exceptional Performance at the CHUM, expands for an ...
January 07 2020 - 8:30AM
DIAGNOS Inc. (“DIAGNOS” or “the Corporation”) (TSX
Venture:ADK) (OTCQB:DGNOF) a leader in early detection of critical
health issues through the use of its FLAIRE platform based on
Artificial Intelligence (AI), announces today the extension of its
technological platform for the automated detection of Diabetic
Retinopathy at the CHUM (Centre hospitalier de l’Université de
Montréal) until the end of June 2020.
Launched in June 2018 in collaboration with the ophthalmology
and endocrinology department, the technology showcase has so far
allowed several hundred diabetic patients from the CHUM to access
cutting edge screening technology. With the support of these two
departments, DIAGNOS will continue to be present at the CHUM until
the end of June 2020.
Our early detection service includes an
automated AI analysis of fundus imagery together with a triage
system according to the degree of severity. This proprietary
service is only available via our CARA platform (Computer Assisted
Retina Analysis).
The DIAGNOS automated screening solution
significantly increases accessibility for diabetic and hypertensive
patients subject to annual screening. Screening is done at the
primary care centers using fundus photography. The process is fast,
painless, and very simple for the patient. The CARA platform will
facilitate identification and expedited triage of patients
suffering from retinopathies who have been referred to the
ophthalmology department following a consultation at the
endocrinology or diabetes clinic.
About DIAGNOSDIAGNOS is a publicly-traded
Canadian corporation with a mission of early detection of critical
health issues through the use of its Artificial Intelligence (“AI”)
tool CARA (Computer Assisted Retina Analysis). CARA is a
tele-ophthalmology platform that integrates with existing equipment
(hardware and software) and processes at the point of care. CARA’s
Artificial Intelligence image enhancement algorithms make standard
retinal images sharper, clearer and easier to read. CARA is
accessible securely over the internet, and is compatible with all
recognized image formats and brands of fundus cameras, and is EMR
compatible. CARA is a cost-effective tool for screening large
numbers of patients in real-time. CARA complies with local
regulations, is FDA cleared for commercialization in the United
States of America is Health Canada licensed for commercialization
in Canada and is CE marking compliant in Europe.
Additional information is available at
www.diagnos.ca and www.sedar.com.
This news release contains forward-looking information. There
can be no assurance that forward-looking information will prove to
be accurate, as actual results and future events could differ
materially from those anticipated in these statements. DIAGNOS
disclaims any intention or obligation to publically update or
revise any forward-looking information, whether as a result of new
information, future events or otherwise. The forward-looking
information contained in this news release is expressly qualified
by this cautionary statement.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
For further information, please contact:
Mr. André Larente, President
DIAGNOS Inc.
Tel: 450-678-8882 ext. 224
alarente@diagnos.ca
Diagnos (TSXV:ADK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Diagnos (TSXV:ADK)
Historical Stock Chart
From Apr 2023 to Apr 2024